HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Hepatocellular CarcinomaLenvatinibPD-1 InhibitorHepatic Arterial Infusion Chemotherapy
Interventions
PROCEDURE

Hepatic arterial infusion chemotherapy

Hepatic arterial infusion chemotherapy (HAIC) procedure was performed with FOLFOX regimen: 85 or 135 mg/m2 oxaliplatin from hour 0 to 2 on day 1400 mg/m2 leucovorin from hour 2 to 4 on day 1, and 400 mg/m2 fluorouracil bolus at hour 5 on the day 1; and 2400 mg/m2 fluorouracil over 46 h on days 1 and 2.

DRUG

Lenvatinib

12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day

DRUG

Tislelizumab

200mg intravenously every 3 weeks

DRUG

Toripalimab

240mg intravenously every 3 weeks

DRUG

Sintilimab

200mg intravenously every 3 weeks

DRUG

Camrelizumab

200mg intravenously every 3 weeks

Trial Locations (1)

100853

RECRUITING

Chinese PLA General hospital, Beijing

All Listed Sponsors
lead

Sun Yat-sen University

OTHER